ArticleBMC complementary medicine and therapies2025
Investigation of differential Multi-Mode antibacterial mechanisms of essential oils of Satureja montana L. and Leptospermum scoparium J.R.Forst. & G.Forst. Against Porphyromonas gingivalis.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Do Adjunctive Therapies with Natural Products Improve Periodontal Clinical Parameters After Non-Surgical Treatment? A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Article
- Current Knowledge of the GenusPharmaceuticals (Basel, Switzerland) · 2026Review
- Research progress and antibacterial mechanisms of plant essential oils as alternative therapies for periodontitis.Frontiers in microbiology · 2026Review
- Multitarget inhibitory effects of lemongrass essential oil on Porphyromonas gingivalis: synergistic regulation of heme utilization, biofilm formation, and the metabolic pathway of ferroptosis.BMC complementary medicine and therapies · 2025Article
- Salivary and Microbiome Biomarkers in Periodontitis: Advances in Diagnosis and Therapy-A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGlobally, according to WHO estimates, severe periodontitis affects over 1 billion people. Porphyromonas gingivalis (P. gingivalis) is a keystone pathogen in the development of chronic periodontitis. Although two commercial essential oils (EOs) derived from Satureja montana L. (EO1) and Leptospermum scoparium J.R.Forst. & G.Forst. (EO2) have demonstrated promising antibacterial potential, their mechanisms against P. gingivalis and the influence of their distinct metabolite profiles remain unclear.
methodsEO metabolite profiles were analyzed using gas chromatography-mass spectrometry. Antibacterial activity was assessed using the disk diffusion, minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and bacterial growth curves. Their effects on hemagglutination, hemolytic, black pigmentation formation, autoaggregation, hydrophobicity, biofilm formation and virulence gene expression were evaluated. Molecular docking simulated interactions between metabolites and the virulence proteins. Cytotoxicity at MIC was tested in RAW264.7 cells using MTT assays.
resultsEO1 showed stronger antibacterial effects than EO2, with inhibition zone diameters (42.06 ± 1.62 versus 40.36 ± 0.47 mm), lower MIC (71.33 versus 305.00 µg/mL), and MBC (142.66 µg/mL versus 1220.00 µg/mL). The bacterial growth curves demonstrated sustained inhibition. EO1 can inhibit P. gingivalis hemagglutination, hemolysis (p < 0.05), and heme accumulation at 1/8 - 1/2 MIC, while EO2 only affected heme accumulation. Both EOs reduced P. gingivalis hydrophobicity levels below 50% at 1/4 to 1/2 MIC and achieved biofilm inhibition rates exceeding 85% at MIC (p < 0.05). The distinct inhibitory mechanisms against the pathogenic processes of P. gingivalis likely stem from their differing metabolite profiles. EO1 was dominated by monoterpenes (56.00 ± 0.55%), and the main metabolites were γ-terpinene (20.20 ± 0.38%), p-cymene (16.01 ± 0.66%), and carvacrol (14.50 ± 0.35%), whereas EO2 contained up to 71.19 ± 0.18% sesquiterpenes, its main metabolites were leptospermone (17.44 ± 0.40%). Molecular docking analysis predicted these metabolites as key active components. Besides, at MIC, cell viability was 86.68% for EO1 and 68.81% for EO2.
conclusionThe comprehensive analysis reveals that EO1 and EO2 exert multi-mode antibacterial effects through different mechanisms. Notably, EO1 demonstrated greater potential against P. gingivalis, which may be attributed to its unique metabolite composition. These findings offer a theoretical foundation and new insights for advancing the application of EOs in the prevention and adjunctive management of periodontitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.